Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Sexual dysfunction ın multiple sclerosis: Gender differences.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
MS related employment and disease modifying treatment in the German working population: 1994-2009.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.
Molecular targets of FTY720 (fingolimod).
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Study Suggests Targeting B Cells May Help with MS
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
[Multiple sclerosis : actuality and therapeutic prospects].
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Celiac disease and multiple sclerosis in the northwest of Iran.
Amiloride Clinical Trial In Optic Neuritis (ACTION)

Pages